Navigation Links
Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon
Date:3/8/2011

xpertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2009 and quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2010, which are on file with the SEC and available on the SEC's website at http://www.sec.gov/.  Additional information will also be set forth in those sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2010, which will be filed with the SEC in the first quarter of 2011.  In addition to the risks described above and in Vanda's annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to updat
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Presents Phase III Iloperidone Efficacy Data
5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... YORK , Aug. 3, 2015   ... global pharmaceutical company Allergan plc is ... Deloitte and Intermountain Healthcare to include ... harness ConvergeHEALTH,s OutcomesMiner analytics platform to generate real-world ... outcomes. "We look forward to expanding ...
(Date:8/3/2015)... VWR (NASDAQ: VWR ), a leading, independent ... of its global website, www.vwr.com , to improve functionality ... site, guests will enjoy enhanced content on a modern and ... site now includes: , a simplified navigation; ... , the ability to search by discipline/industry. ...
(Date:8/3/2015)... 3, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ... Second Quarter 2015 Investor Conference Call and webcast at 4:30 ... The call will cover an update on Merrimack,s progress ... financials. A press release detailing the information to be ... of Monday, August 10. Investors and the general public ...
Breaking Medicine Technology:ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 3ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 4VWR's New Website Redesign Provides Improved Functionality for Customers 2Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2
... , ST. LOUIS , Feb. 1 ... The TODAY Show featured Dr. Mauricio Arruda ... Heart & Vascular Institute in Cleveland, Ohio , performing ... its broadcast this morning.  The patient was a 69 year ...
... DIEGO , Feb. 1 CareFusion (NYSE: ... today that it has entered into a 5-year sole source ... top ten Catholic health systems in the U.S., to upgrade ... further into the operating rooms and cath labs. , CareFusion,s ...
Cached Medicine Technology:Stereotaxis System Procedure Featured on NBC's The TODAY Show 2CareFusion Announces 5-Year, Sole Source Pyxis(R) Perioperative Solutions Agreement With CHRISTUS Health 2CareFusion Announces 5-Year, Sole Source Pyxis(R) Perioperative Solutions Agreement With CHRISTUS Health 3CareFusion Announces 5-Year, Sole Source Pyxis(R) Perioperative Solutions Agreement With CHRISTUS Health 4
(Date:8/3/2015)... FL (PRWEB) , ... August 03, 2015 , ... ... to date of its industry-defining contract lifecycle management solution, as well as announced ... designed to increase the speed and ease of contract management tasks as well ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... the development of it’s new program “Designing Secure Healthcare Systems” This three-day, ... and technology leaders from healthcare organizations with access to the tactics, techniques and ...
(Date:8/3/2015)... ... ... A July 13 article from The Daily Mail titled "Jab That ... Can Last 'For Five Weeks'" discusses the use of stem cells to help ... harvesting stem cell-rich bone marrow from the hip, known as bone marrow stromal cells ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... insurance brokerage firm, announced today that Joe Williams has joined its growing California ... and delivering HUB's differentiated service model to his clients. Mr. Williams will be ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... management and investigative services, has introduced a new logo and comprehensive brand ... that improve business outcomes for its customers. EMSI’s new tagline, “Powerful Information. ...
Breaking Medicine News(10 mins):Health News:Novatus Unveils Milestone Software Release 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2
... WASHINGTON, Oct. 8 The U.S. Department of,Labor ... 700,jobless workers with partial premium payments for health ... nearly 700 North Carolinians who are,looking for work ... afford health insurance for themselves and their families," ...
... YORK, Oct. 8 Weight Watchers,International, Inc. (NYSE: ... Steven,C. McCormick to serve as its President, North ... with extensive consumer product,operations and general management experience, ... its North American products,publishing and licensing businesses and ...
... their levels correlate with cardiovascular trouble , , WEDNESDAY, Oct. ... activity of genes in white blood cells might someday ... of chest pain, researchers report. , The finding is ... the first issue of a new American Heart Association ...
... Sinobiomed Inc.,("Sinobiomed", or "the Company") (OTC Bulletin ... of Directors voted on October 2, 2008 to ... Officer under a,Corporate Consulting Services Agreement to be ... Choong has been appointed to the Company,s audit,committee. ...
... (OTC Bulletin Board:,VYTC) today announced that effective October ... as an independent scientific consultant to Vyta Corp.,Dr. ... Development at,BIOAGRA, LLC, a joint venture, equally owned ... 15, 2008, Vyta Corp announced its filing of,foreclosure ...
... 8 Dr. Jane Hightower -- widely,acknowledged as the ... who regularly consume certain types of fish -- today,released ... inform and protect,the public from the risks of mercury ... Hightower has released a new book, Diagnosis:,Mercury: Money, Politics, ...
Cached Medicine News:Health News:Weight Watchers Names Steven C. McCormick as President, North America 2Health News:Weight Watchers Names Steven C. McCormick as President, North America 3Health News:Blood Cell Genes May Signal Heart Disease 2Health News:Sinobiomed Directors Confirm Hiring of New Chief Financial Officer 2Health News:Vyta Corp Announces Engagement of Dr. Nino Sorgente as Independent Consultant 2Health News:New Evidence Highlights Dangers of Mercury Toxicity in Fish 2
Inquire...
Richardson Retractor...
A full, rounded look that adds greater dimension to the breast. Moderate base, with a higher profile than our Style 1600 implant....
... implant is an expanded porous polytetrafluoroethylene,material ... repair of the soft tissues of ... in sheets and shaped geometries with ... implant strands are packaged with and,without ...
Medicine Products: